Glenmark Launches Winlevi in Key European Markets

Glenmark Pharmaceuticals Ltd. announced the launch of its acne treatment cream, Winlevi (clascoterone 10 mg/g), in key European markets through its subsidiary Glenmark Specialty S.A. This marks Glenmark's first New Chemical Entity (NCE) launch in Europe. The product, authorized by the European Commission, is for treating acne vulgaris in adults and adolescents. Glenmark is executing direct launches in several regions and through strategic partners in others. Winlevi is a first-in-class topical androgen-receptor inhibitor, offering a new treatment option for a common dermatological condition. This launch strengthens Glenmark's dermatology portfolio and its branded business in Europe.